Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2013

View Archived Issues

A groundbreaking technique to aid accurate network imaging in intact brains

Dual mTORC1/2 inhibitor shows promise as immunosuppressant in vivo

The development of probes to determine the therapeutic potential of epigenetic inhibitors

Clinical results presented for a novel cancer immunotherapy

Phase IIa studies indicate GFT-505 may reduce remnant cholesterol

Helsinn and Vifor sign agreement for netupitant/palonosetron fixed-dose combination

Bayer seeks approval for riociguat in Japan

AbbVie and Galapagos add Crohn's disease to GLPG-0634 collaboration

Novo Nordisk reports results from first phase III trial of N9-GP

FDA clears Oramed's IND to test ORMD-0801 oral insulin

Otsuka reports on regulatory and clinical developments of fiscal 2012

Curie-Cancer and Roche partner further on translational research programs

Sanofi reports topline data from pivotal phase III JAKARTA study

XenoPort ends development of arbaclofen placarbil for MS spasticity

Bydureon launched in Japan

Breakthrough therapy designation for Synageva's sebelipase alfa

Astex Therapeutics designs novel FGFR inhibitors

Scientists at GlaxoSmithKline present new agents for cancer

FDA grants orphan drug status to ibrutinib, terguride and HIRMAb-IDS

New mTOR inhibitors disclosed by Novartis

Novel cannabinoid CB2 receptor agonists synthesized at Roche

Pfizer ends phase III trial of inotuzumab ozogamicin

Sanofi divulges novel PKC-beta 2 inhibitors

FDA advisory committee sets date to review MoxDuo NDA

Reva Medical offers update on development of ReZolve and ReZolve2 scaffolds

High efficacy and long duration of a new formulation of NAG-MLP and chol-siRNAs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...